So there are companies that are covering our stock. Let’s see here. Are you surprised to see this increase in revenue in the first two months of ‘24, considering the next [indiscernible] commercialization? What do you attribute this to? Really, again, we attribute the growth that we’ve been seeing to the fact that there has been this convergence of awareness of the product amongst key opinion leaders there’s been really exciting clinical outcomes showing the intense need and the benefit of utilizing blood volume analysis and the need of customers to solve this problem. So just to review for a second. Studies have come out showing that you can cut the length of stay for heart failure patients, for example, by 2.5 days when they receive our test at the beginning of their hospital day.
That translates into a savings of thousands and thousands of dollars of cost of care of that kind of patient. Now why does that work? Well, if you start by diagnosing what’s wrong with the patient from the beginning, the treatment is optimized, the care is more effective. They get out of the hospital sooner, they’re much less likely to die and they’re much less likely to readmit. This is a huge problem across the entire health care system. In other words, value-based care really at the centerpiece of everything that’s going on in American Medicine. It’s something that wasn’t true 10 years ago as much, but now it really is. So when we go to hospital administrators, we talk to service in directors, we say, what are you focused on? What do you care about?
They all said, we’re really interested in understanding how to improve the health economics of treating these patients more effectively. Daxor has an inexpensive solution to a rate cost and problem that they’re all really focused on. And our messaging has become very clean and very clear. We have a really strong sales and marketing team over a dozen people that are focused on that. And I think that the word is getting out. The customers are now telling other customers about how they’ve been getting really good results with it. I think that, that’s just adding to the groundswell that is increasing the awareness and desire for front. Let’s see questions the — all right. So the last question that I’ll seek to address a little bit is around the cadence of the business and giving people a sense of how to think about it.
I want to emphasize that all the numbers that I’ve given around changes in revenue and changes in sales, et cetera, are unaudited numbers. Because, again, the audited numbers that we have are from the — or from the filings that you can find in the NCSR, numbers around our operating company because we file consolidated statements are unaudited. So I just want to make sure that investors are aware of that. In terms of understanding where we’re at, this is something where I think that the company is clearly focused on wanting to penetrate the market in a substantial way. When we think about hospital sales and what hospitals are capable of doing a typical hospital might start out doing 100, 200, 300 tests a year, 500 to 1,000 starts to look like really ample penetration if you’re talking about one indication like part failure, you had in critical care and ology, cardiorenal concepts, etc.
You start treated a typical hospital could have as much as 1,500, 2,000 tests a year total addressable market. That’s why our next-generation systems are really important because of the speed and utility that they have. That’s where what we’re really aiming to do is to really scale up into this business in a really profound way. At this point, the numbers start to look very compelling. As I said earlier, you start to look at what our revenue numbers look like as we achieve marker of 10,000 tests. If you look at the ability of our facility to produce 20x that number of doses and you start to get a feeling for what the total revenues with our existing footprint that we could scale into. We’ll be looking to step up into that and giving more clarity around that as we achieve our milestones.
With that, I’m going to thank you for your time and attention and all of your thoughtful questions. And I’ll turn it back over to Bob, if there’s anything else that we need to say before closing. Bob, you are on mute.
Robert Michel: Yes. I’d just like to thank everybody for joining the call. And as Michael said, as we reached these milestones, we will be making announcements for the path forward. And it’s a very exciting time to be at Daxor and to be an investor at Daxor. So thank you very much for your support.